The Safety and Tolerability of STSA-1002 Following Subcutaneous Injection in Healthy Subjects
Condition: Antineutrophil Cytoplasmic Antibody Associated Vasculitis Intervention: Drug: STSA-1002 subcutaneous injection Sponsor: Staidson (Beijing) Biopharmaceuticals Co., Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 27, 2023 Category: Research Source Type: clinical trials
The Safety and Tolerability of STSA-1002 Following Subcutaneous Injection in Healthy Subjects
Condition: Antineutrophil Cytoplasmic Antibody Associated Vasculitis Intervention: Drug: STSA-1002 subcutaneous injection Sponsor: Staidson (Beijing) Biopharmaceuticals Co., Ltd Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 27, 2023 Category: Research Source Type: clinical trials
The Safety and Tolerability of STSA-1002 Following Subcutaneous Injection in Healthy Subjects
Condition: Antineutrophil Cytoplasmic Antibody Associated Vasculitis Intervention: Drug: STSA-1002 subcutaneous injection Sponsor: Staidson (Beijing) Biopharmaceuticals Co., Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 27, 2023 Category: Research Source Type: clinical trials
Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms (CAA) in Kawasaki disease (KD): the KD CAA prevention (KD-CAAP) trial protocol
DiscussionSeveral recent studies have indicated that coronary complications associated with KD across Europe are much higher than early trials of IVIG had initially suggested. KD-CAAP directly addresses this issue by exploring the therapeutic benefit of adjunctive corticosteroids in unselected KD cases. If we find that corticosteroids prevent CAA and are safe, this is a cheap and widely available intervention that could be implemented immediately for the benefit of children.Trial registrationISRCTN71987471- March 31, 2020; Eudract 2019 –004433-17. (Source: Trials)
Source: Trials - January 26, 2023 Category: Research Source Type: clinical trials
Analysis of Imaging Features From Patients Treated With Brolucizumab in the Post-marketing Setting With Reports of Retinal Vasculitis and/or Retinal Vascular Occlusion
Conditions: Intraocular Inflammation; Retinal Vascular Occlusion Intervention: Other: Brolucizumab Sponsor: Novartis Pharmaceuticals Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 20, 2022 Category: Research Source Type: clinical trials
